A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available ...

Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...

The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for ...

In the Phase 3 ACHIEVE-3 trial, oral orforglipron demonstrated superior HbA1c and weight reduction vs oral semaglutide in ...

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Add Yahoo as a preferred source to see more of our stories on Google. (Guido Mieth/DigitalVision/Getty Images) We may have a new champion when it comes to pills that can manage both blood sugar levels ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic ...

The United Laboratories International Holdings Limited and Novo Nordisk A/S NVO reported Wednesday topline data from a phase ...

GLP-1s have been a breakthrough for obesity and diabetes. A 2022 study examined data from trials of GLP-1s in nearly 16,000 patients with diabetes, and showed that the drugs were associated with a 53% ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral semaglutide, made by Novo Nordisk, suggests the former pill may have the edge ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds ...